Over the past months, Ocugen (NASDAQ:OCGN) has come into considerable focus among investors after the company announced that it struck up a partnership with Bharat Biotech for developing and distributing the COVID 19 vaccine Covaxin.
More importantly, it has now been established that Covaxin also works against the different strains of COVID 19 and that has made many wonders whether Ocugen could end up being a major winner from among companies that are involved in this space.
In a chat between two Motley Fool contributors, Kevin Speights and Brian Orelli, the latter stated that while it is true that the effectiveness against different strains is positive there are other things to worry about. He states that investors should be more focused on Covaxin actually getting the much-needed approval at this point. While Speights argued that a vaccine that is effective against multiple strains has a bigger chance of success, Orelli stated that it is unlikely that the serum laboratory experiments are going to be accepted by the FDA.
Writing for business and finance publishers has become his passion over the last decades after he completed a master’s degree in Financial Management. Sharing some opinions and forecasts to thousands of readers is a routine job for him but he never promises to invest in one stock.